Ask AI
Bill116th CongressFiled Apr 29, 2019Health
H.R. 2374

Stop STALLING Act

Bill journey · stage 2 of 5

Under committee review

Filed
Comm.
Floor
Both
Law

What it doesSummary reported to house (Dec 24, 2020)

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

What just happenedDec 24, 2020

Placed on the Union Calendar, Calendar No. 577.

Who’s behind it

Rep. Jeffries, Hakeem S. [D-NY-8](D-NY)Sponsor
7 cosponsors4 D3 R
Read on Congress.gov
7cosponsors1committees8actions2related bills8subjects
  1. Dec 24, 2020CalendarsH12410

    Placed on the Union Calendar, Calendar No. 577.

  2. Dec 24, 2020CommitteeH12200

    Reported by the Committee on Judiciary. H. Rept. 116-694.

    Judiciary Committee
  3. Dec 24, 2020Committee5000

    Reported by the Committee on Judiciary. H. Rept. 116-694.

    Judiciary Committee
  4. Apr 30, 2019Committee

    Ordered to be Reported by Voice Vote.

    Judiciary Committee
  5. Apr 30, 2019Committee

    Committee Consideration and Mark-up Session Held.

    Judiciary Committee
  6. Apr 29, 2019IntroReferralH11100

    Referred to the House Committee on the Judiciary.

    Judiciary Committee
  7. Apr 29, 2019IntroReferralIntro-H

    Introduced in House

  8. Apr 29, 2019IntroReferral1000

    Introduced in House

Reported to HouseDec 24, 20207

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Introduced in HouseApr 29, 2019

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Stop STALLING Act — Informed